FIELD: chemistry.
SUBSTANCE: present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical compositions containing said prodrug. Besides, it relates to their use as medicinal agents for treating diseases which can be treated with growth hormone, and to methods of treatment. It also relates to methods of using such a polymeric prodrug of human growth hormone or a pharmaceutical composition.
EFFECT: disclosed are novel polymeric hGH prodrugs.
22 cl, 9 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
RTN PRODRUGS | 2017 |
|
RU2747316C2 |
PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATMENT OF GROWTH HORMONE-RELATED DISEASES IN HUMANS | 2019 |
|
RU2802215C2 |
HYDROCARBON GEL-BASED PRODRUGS | 2013 |
|
RU2647729C2 |
PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING GROWTH HORMONE-ASSOCIATED DISEASES IN HUMANS | 2014 |
|
RU2689336C2 |
VEGF NEUTRALISING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS | 2013 |
|
RU2673881C2 |
CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
DIAGNOSIS, PREVENTION AND TREATMENT OF JOINT DISEASES | 2013 |
|
RU2682676C2 |
CNP PRODRUGS | 2016 |
|
RU2824988C1 |
PEGYLATED COMPOUNDS OF RECOMBINANT HUMAN GROWTH HORMONE | 2009 |
|
RU2530714C9 |
LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
Authors
Dates
2020-04-13—Published
2015-11-17—Filed